| scholarly article | Q13442814 |
| P50 | author | Ingemar Ernberg | Q5718027 |
| Markus Maeurer | Q47502460 | ||
| Mats Remberger | Q62670226 | ||
| Olle Ringden | Q89625226 | ||
| Thomas Poiret | Q96096338 | ||
| Lalit Rane | Q117232094 | ||
| Raija K Ahmed | Q117232096 | ||
| Isabelle Magalhaes | Q42089319 | ||
| P2093 | author name string | Qin Li | |
| Jacek Winiarski | |||
| Qingda Meng | |||
| Nalini Vudattu | |||
| Ziming Du | |||
| Åsa Gustafsson-Jernberg | |||
| Jiezhi Zou | |||
| P2860 | cites work | Epstein-Barr virus genomes are found predominantly in IgA-positive B cells in the blood of healthy carriers | Q44654555 |
| Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation | Q45351795 | ||
| Epstein-Barr virus genome load is increased by therapeutic vaccination in HIV-l carriers, and further enhanced in patients with a history of symptomatic primary infection | Q45355729 | ||
| Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression | Q45406910 | ||
| Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. | Q45744882 | ||
| Two signal activation as an explanation of high zone tolerance: a mathematical exploration of the nature of the second signal. | Q52374035 | ||
| Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. | Q52603060 | ||
| Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load. | Q54448924 | ||
| EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. | Q54543998 | ||
| Epstein-Barr Viral Load and Disease Prediction in a Large Cohort of Allogeneic Stem Cell Transplant Recipients | Q61865935 | ||
| Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection | Q70082032 | ||
| Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides | Q73746921 | ||
| Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning | Q26795740 | ||
| Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults | Q33817588 | ||
| The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection | Q33860858 | ||
| Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay | Q33958107 | ||
| DNA sequence and expression of the B95-8 Epstein-Barr virus genome. | Q34245077 | ||
| Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions | Q34576340 | ||
| Soluble factors produced by activated CD4+ T cells modulate EBV latency | Q35749824 | ||
| The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression | Q35818660 | ||
| Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals | Q35865462 | ||
| "Sneaking through": a T-cell-dependent phenomenon | Q36045731 | ||
| Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory | Q36367550 | ||
| Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? | Q37285658 | ||
| Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation | Q37552052 | ||
| TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions | Q37813013 | ||
| Determining EBV load: current best practice and future requirements | Q38079834 | ||
| Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. | Q38126766 | ||
| Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice | Q38358700 | ||
| Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCR. | Q38426617 | ||
| How I treat posttransplant lymphoproliferative disorders | Q38589013 | ||
| Immune Evasion by Epstein-Barr Virus | Q38597254 | ||
| The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients | Q38615024 | ||
| TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation | Q38958779 | ||
| Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. | Q39463952 | ||
| Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. | Q39493969 | ||
| Suppressor Cells: Permitters and Promoters of Malignancy? | Q39805019 | ||
| Recent trends in tumor immunology | Q40037077 | ||
| Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care | Q40572369 | ||
| Suppressor T cells in low zone tolerance I. Mode of action of suppressor cells | Q40649496 | ||
| Suppressor T cells in low zone tolerance II. Characterization of suppressor T and amplifier cells by physical and serological methods | Q40664068 | ||
| T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells | Q41051031 | ||
| The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder | Q41219311 | ||
| Adoptive cellular immunotherapy for EBV lymphoproliferative disease | Q41561751 | ||
| Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. | Q42244554 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | 30230-30240 | |
| P577 | publication date | 2016-04-19 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning | |
| P478 | volume | 7 |
| Q47992798 | A Dynamic Model of Immune Responses to Antigen Presentation Predicts Different Regions of Tumor or Pathogen Elimination |
| Q89748152 | Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes |
| Q64103674 | Human cord blood-derived viral pathogens as the potential threats to the hematopoietic stem cell transplantation safety: A mini review |
| Q61797705 | Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation |
Search more.